Profitable MorphoSys Proves Value of Technology Partnership Model
This article was originally published in The Pink Sheet Daily
A milestone payment from long-time partner Novartis helped German antibody company MorphoSys report record revenues, supporting a 23% increase in R&D spend without the need to tap investors.
You may also be interested in...
MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.